Bayer
Whippany
New Jersey
United States
902 articles about Bayer
-
Bayer will co-create a novel target identification platform that leverages Aignostics’ artificial intelligence technology and proprietary multimodal patient cohorts.
-
Bayer and Aignostics to collaborate on next generation precision oncology
3/14/2024
Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence -powered approaches with applications in precision oncology drug research and development.
-
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
3/4/2024
BridgeBio Pharma, Inc. and Bayer announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe.
-
As BridgeBio’s acoramidis inches closer to an FDA approval decision, Bayer on Monday inked a European licensing agreement for the transthyretin amyloid cardiomyopathy treatment.
-
From entering college in China at just 15 to co-inventing a drug for Bayer, Mei’s career journey has been far from average. Now CMO at Editas, he’s not done yet.
-
Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations
2/26/2024
Bayer announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.
-
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis
2/20/2024
Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).
-
Bayer AG Enters Into Agreement With TetraScience to Ignite Innovation by Maximizing the Value of Its Scientific Data
2/5/2024
Bayer AG (BAYRY), a leading global pharmaceutical and biotechnology company, and TetraScience, the Scientific Data and AI Cloud company, today announced an agreement aimed at maximizing the value of scientific data and driving innovation.
-
Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division
1/22/2024
Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024.
-
The sweeping changes are meant to “reduce hierarchies” and “accelerate decision-making” as Bayer weathers several business crises and continues to suffer from the fallout of its disastrous Monsanto acquisition.
-
Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium
1/17/2024
Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.
-
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause
1/8/2024
Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant.
-
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
1/8/2024
Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo.
-
Bayer and CrossBay Medical to develop novel Intrauterine System Inserter
11/30/2023
Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.
-
Bayer and Hurdle launch precision health strategic partnership
11/28/2023
Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging.
-
Bayer Commits to Veeva Vault CRM and Veeva OpenData Globally
11/27/2023
Veeva Systems (NYSE: VEEV) today announced that Bayer will be among the first top 20 biopharmas to move to Veeva Vault CRM worldwide, while also standardizing global customer data with Veeva OpenData.
-
Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
11/22/2023
Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline for an investigational contrast agent as well as new innovations in the area of Artificial Intelligence.
-
Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’ and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.
-
Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination
11/17/2023
Bayer is voluntarily recalling one lot of Vitrakvi® Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level.
-
Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)
11/15/2023
Ionetix Corporation announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 with Bayer.